The plan will cover administration of the booster for those with cancer or who are immunocompromised.
BlueCross BlueShield of Tennessee will cover the administration cost for a COVID-19 booster for those who are moderately to severely immunocompromised, including those undergoing cancer treatment. Organization executives said in a statement that members in commercial Blue Network S, P and L, as well as Medicare Advantage, BlueCare Tennessee and BlueCare Plus Tennessee will also be able to get a booster without any out-of-pocket costs.
“It’s our responsibility to support members seeking to protect themselves against COVID-19. Research has demonstrated the clear value of a booster to reduce risk, which ultimately will help communities facing the Delta variant surge,” Andrea Willis, M.D., chief medical officer for BlueCross.
The Centers for Disease Control recommends COVID-19 vaccine boosters for those who:
Additional, the plan is waiving member costs for medically necessary COVID-19 testing until the end of the national public health emergency, and last year made permanent coverage for in-network telehealth visits for members with employer-based or individual plans.
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More